Wolf Hill Capital is bullish on Constellium NV (NYSE:CSTM), a Netherlands-based developer of aluminum products. Constellium had a solid year in 2017, with the company’s share price surging more than 70%. The aluminum industry has struggled lately due low prices aimed weak demand. However, the metal industry is getting ready for better days in 2018, thanks to a growing demand from the aerospace and automotive sectors. Wolf Hill is confident about the aluminum industry in 2018, and in its Q4 investor letter, the fund talked about Constellium as well as other companies. In this article, our focus is on Wolf Hill’s investment thesis about Constellium.
Here are Wolf Hill’s comments about the aluminum stock:
In recent quarterly letters, we discussed in detail our thesis behind our largest position, Constellium, and why we thought this aluminum fabricator offered the potential for a 4-5x potential return. As this remains our largest position due to price appreciation, a quick update is in order. During the quarter, CSTM partially recapitalized its balance sheet by simultaneously issuing 25 million shares of stock and issuing a new unsecured bond. The proceeds from these capital markets transactions were used to retire several issues of outstanding bonds and to strengthen the company’s balance sheet. While these transactions served to partially de-risk the company’s levered balance sheet, they came at a steep cost in terms of shareholder dilution. The net result is that the secondary stock sale took the wind out of the sails of those looking for a quick sale to a strategic buyer.
That said, the de-leveraging impact of the recapitalization along with continued solid operational execution and secular tailwinds in CSTM’s key end-market should provide the foundation for the next leg of CSTM’s resurgence. In fact, as we put the finishing touches on this letter, Bloomberg News is reporting that Mumbai-listed Hindalco is close to announcing a transaction to acquire privately held CSTM competitor, Aleris Corp. for $2.5b. This would represent 12.1X LTM EBITDA multiple for Aleris, a rich valuation that highlights the scarcity value and desirability of domestic aluminum fabrication assets. Applying the same multiple to CSTM would result in a $30+ stock price, 3x where it is currently trading. Just saying…
Credit: Pixabay.com
Constellium NV (NYSE:CSTM) is a $1.80-billion market cap maker of aluminum products for a range of markets and applications, including aerospace, automotive and packaging. Shares of the company are up 20.18% since the beginning of the year, while the value of the stock has moved up whopping 78.67% over the past 12 months. The stock, currently trading at $13 per share, has a consensus average target price of $14.17 and a consensus average recommendation of OVERWEIGHT, according to analysts polled by FactSet.
Constellium reported a solid performance for its third quarter, with revenue increasing 7% year-over-year to €1.3 billion mainly due to higher aluminum prices. The company posted net income of €21 million for the third quarter, up compared to €15 million in the same quarter of 2016. Its adjusted EBITDA was €111 million, up 15% year-over-year due to improved results from the aerospace and transportation and the automotive structures and Industry business units.
Further, Constellium updated its guidance for adjusted EBITDA growth in 2017 to around 13%. It expects adjusted EBITDA growth in the high single digits annually for the next three years, leading to more than €500 million of adjusted EBITDA in 2020. The company is set to report its fourth-quarter financial results on February 22.
Meanwhile, Constellium NV (NYSE:CSTM) isn’t very popular stock among hedge funds tracked by Insider Monkey. There were 36 funds in our database that see a value in the aluminum products developer, including North Run Capital, Bronson Point Partners, and SkyTop Capital Management.
Warren Buffett never mentions this but he is one of the first hedge fund managers who unlocked the secrets of successful stock market investing. He launched his hedge fund in 1956 with $105,100 in seed capital. Back then they weren’t called hedge funds, they were called “partnerships”. Warren Buffett took 25% of all returns in excess of 6 percent.
For example S&P 500 Index returned 43.4% in 1958. If Warren Buffett’s hedge fund didn’t generate any outperformance (i.e. secretly invested like a closet index fund), Warren Buffett would have pocketed a quarter of the 37.4% excess return. That would have been 9.35% in hedge fund “fees”.
Actually Warren Buffett failed to beat the S&P 500 Index in 1958, returned only 40.9% and pocketed 8.7 percentage of it as “fees”. His investors didn’t mind that he underperformed the market in 1958 because he beat the market by a large margin in 1957. That year Buffett’s hedge fund returned 10.4% and Buffett took only 1.1 percentage points of that as “fees”. S&P 500 Index lost 10.8% in 1957, so Buffett’s investors actually thrilled to beat the market by 20.1 percentage points in 1957.
Between 1957 and 1966 Warren Buffett’s hedge fund returned 23.5% annually after deducting Warren Buffett’s 5.5 percentage point annual fees. S&P 500 Index generated an average annual compounded return of only 9.2% during the same 10-year period. An investor who invested $10,000 in Warren Buffett’s hedge fund at the beginning of 1957 saw his capital turn into $103,000 before fees and $64,100 after fees (this means Warren Buffett made more than $36,000 in fees from this investor).
As you can guess, Warren Buffett’s #1 wealth building strategy is to generate high returns in the 20% to 30% range.
We see several investors trying to strike it rich in options market by risking their entire savings. You can get rich by returning 20% per year and compounding that for several years. Warren Buffett has been investing and compounding for at least 65 years.
So, how did Warren Buffett manage to generate high returns and beat the market?
In a free sample issue of our monthly newsletter we analyzed Warren Buffett’s stock picks covering the 1999-2017 period and identified the best performing stocks in Warren Buffett’s portfolio. This is basically a recipe to generate better returns than Warren Buffett is achieving himself.
You can enter your email below to get our FREE report. In the same report you can also find a detailed bonus biotech stock pick that we expect to return more than 50% within 12-24 months. We initially share this idea in October 2018 and the stock already returned more than 150%. We still like this investment.
Free Report Reveals
Warren Buffet's Secret Recipe
Our Price: $199FREE
We may use your email to send marketing emails about our services. Click here to read our privacy policy.
